Navigation Links
VCU medical team recommends preventive antibiotic for COPD sufferers
Date:7/26/2012

RICHMOND, Va. (July 26, 2012) Patients suffering from the chronic lung condition COPD, which is the third-leading cause of death and disability in the United States, may benefit greatly from a three-times-a-week dose of an antibiotic, according to a study by Virginia Commonwealth University physicians published in today's issue of the New England Journal of Medicine.

Approximately 24 million Americans suffer from COPD, or chronic obstructive pulmonary disease, which creates recurrent, acute episodes of severe shortness of breath, cough and sputum production. Every episode can threaten the lives of the patients and lead to additional lung function decline.

The VCU team, led by Richard P. Wenzel, M.D., professor and former chair of the VCU Department of Internal Medicine in the VCU School of Medicine, and former president of the International Society for Infectious Diseases, performed a critical review of current clinical studies, reviewed the pharmacology and adverse effects of the antibiotic, azithromycin, and examined the risks and benefits of a regimen of a Monday, Wednesday and Friday dose of azithromycin.

Wenzel and colleagues Alpha A. Fowler III, M.D., professor and chair of the Division of Pulmonary Disease and Critical Care Medicine, and Michael B. Edmond, M.D., M.P.H., professor and chair of the Division of Infectious Diseases, concluded that a large segment of COPD sufferers could benefit from the preventive approach.

According to Wenzel, the proposed approach for use of azithromycin for the prevention of COPD exacerbations has not been endorsed by any of the large pulmonary and infectious disease organizations, including the GOLD group. But he said that the current review is compelling enough that these groups may move to revisit their current guidelines.

"This approach has the potential to eliminate one-third of the severe exacerbations each year among patients with COPD," said Wenzel.

However, according to Wenzel, this protocol may not be suitable for every patient. Some may suffer adverse consequences with a year-long use of azithromycin, such as hearing loss, antibiotic resistance and heart rhythm disturbances. The VCU team reviewed many of the studies of the drug and made recommendations to minimize the unwanted consequences yet provide relief to a large segment of the COPD patients.

In the study, the authors have outlined a list of proposed criteria for choosing which patients would benefit and who should not take the proposed regimen. They would exclude those with a high risk of cardiovascular disease who may be prone to dangerous cardiac rhythm disturbances; those on drugs already known to affect the electrocardiogram adversely and that might interact with the antibiotic azithromycin; and those with hearing loss.

Wenzel and his colleagues noted that an earlier study based on a large clinical trial indicated that if approximately three people must be treated to prevent one annual exacerbation, then the cost to prevent an exacerbation would be $3,564 for daily dosing, or $1,545 for dosing three times a week.

They also noted that a recent study in Canada showed that the cost of a hospital stay following an acute exacerbation of COPD was $9,557 Canadian dollars. In 2000, 726,000 patients were hospitalized in the U.S. with acute exacerbations of COPD.


'/>"/>
Contact: Sathya Achia Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Physician Groups Call for Fewer Medical Tests
2. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
3. CAM therapy combined with conventional medical care may improve treatment of lower back pain
4. Image share project gives patients and physicians anytime, anywhere access to medical images
5. Researchers determine vitamin D blood level for reducing major medical risks in older adults
6. Biomedical researchers receive Hartwell Foundation awards
7. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
8. Fitness in Middle Age Lowers Medical Costs Later: Study
9. Ben-Gurion U. and Cincinnati Childrens Hospital to develop pediatric-specific medical technologies
10. Gene Tests May Not Drive Patients to More Medical Care
11. University studies and career expectations of medical students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Healthful Balance announces ... company, owned and operated by Ed Stroup, was created to offer the highest ... highest level of customer service. Healthful Balance products can be purchased online through ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... well as Palm Desert, is opening a new office in San Clemente, California ... magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling with major depression. ...
(Date:1/17/2017)... , ... January 17, 2017 , ... A prescription medication ... of the fourth Cradle to Cradle Product Design Challenge , the Cradle ... a series of six circular design challenges scheduled to run through early 2018. The ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare company ... clinical study for its dental gel that shows significant reduction in plaque levels and ... triclosan. The study was conducted at the Beckman Laser Institute at UC Irvine and ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Many people make New Year’s resolutions or renew ... Mondavi is making it easier for people who want to kick off 2017 with ... and existing patients. , These special offers include: , , ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... -- Research and Markets has announced the addition of ... to their offering. ... The global fluoropolymer market in the healthcare industry to grow ... Global Fluoropolymer Market in the Healthcare Industry 2016-2020, has been ... experts. The report covers the market landscape and its growth prospects ...
(Date:1/17/2017)... Jan. 17, 2017 Following an initial ... praised the Food and Drug Administration,s (FDA,s) final ... Drug Products by Pharmacies and Outsourcing Facilities." In ... limitation on pre-packaging -- which would have put ... to long term care (LTC) pharmacies.  ...
(Date:1/17/2017)... ReportsnReports.com adds "Anaphylaxis - Pipeline Review, H2 2016" ... Anaphylaxis,s therapeutic pipeline with comprehensive information on the therapeutic development ... assessment by drug target, mechanism of action (MoA), route of ... featured news and press releases. ... Complete report on H2 2016 pipeline ...
Breaking Medicine Technology: